Dre Gjorgjieva's research interests
Around 403.000 patients per year are diagnosed with renal carcinomas worldwide. Renal carcinomas are promoted by several factors such as obesity/diabetes, chronic kidney disease, smoking, toxin exposure, genetic predispositions and high blood pressure.
This diverse array of risk factors leads to very strong differences in terms of tumor morphology, mutational profile and metabolic status and testifies for the need to deepen our understanding of the pathological processes involved in this disease in order to develop novel therapeutic approaches to fight renal cancer.
Dr Gjorgjieva’s research aims therefore at deciphering the different molecular mechanisms involved in the incidence and progression of renal cancer.
She is working on the development of an in vivo model of renal carcinoma that better mimics the pathology observed in humans and might open new therapeutic avenues.
- Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease
Molecular Therapy, 2019, 15:383–91.
Cell Stress, 2019, 28;3(3):86-99.
- Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia
Journal of Inherited Metabolic Disease, 2018, 41:955–63.
- Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia
Journal of Hepatology, 2018, 69:1074–87.
- Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non-alcoholic fatty liver disease-like context
Molecular Metabolism, 2018,16:100–15.
- Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases
Molecular Therapy, 2018, 26:1771–82.
Molecular Therapy, 2017, 26:890–901.
Human Molecular Genetics, 2016, 25:3784–97.
- Mechanisms by Which Metabolic Reprogramming in GSD1 Liver Generates a Favorable Tumorigenic Environment
Journal of Inborn Errors of Metabolism & Screening, 2016, vol.4, e160020.